Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term 7689-03-4 (Camptothecin). Found 3 abstracts

Meropol NJ, Gold PJ, Diasio RB, Andria M, Dhami M, Godfrey T, Kovatich AJ, Lund KA, Mitchell E, Schwarting R. Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer.[see comment]. Journal of Clinical Oncology. 2006 Sep;24(25):4069-77.
Engstrom PF, Benson AB, Chen YJ, Choti MA, Dilawari RA, Enke CA, Fakih MG, Fuchs C, Kiel K, Knol JA, Leong LA, Ludwig KA, Martin EW, Rao S, Saif MW, Saltz L, Skibber JM, Venook AP, Yeatman TJ, National Comprehensive Cancer N. Rectal cancer clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network. 2005 Jul;3(4):492-508.
Langer CJ. Irinotecan in advanced lung cancer: focus on North American trials. Oncology (Huntington). 2004 Jun;18(7 Suppl 4):17-28.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term 7689-03-4 (Camptothecin)

Camptothecin aa [Analogs & Derivatives] 7689-03-4 (Camptothecin) dt [Drug Therapy] Antineoplastic Combined Chemotherapy Protocols tu [Therapeutic Use] Adjuvant Radiotherapy Use] Lung Neoplasms 0 (Antineoplastic Combined Chemotherapy Protocols) tu [Therapeutic 951-77-9 (Deoxycytidine) 100286-90-6 (irinotecan) Neoplasm Staging 51-21-8 (Fluorouracil) ad [Administration & Dosage] Deoxycytidine Fluorouracil Medical Oncology 0 (IFL protocol) Non-Small-Cell Lung Carcinoma Immunohistochemistry Type I) EC 5-99-1-2 (DNA Topoisomerases Thymidylate Synthase Proportional Hazards Models Logistic Models Enzyme Inhibitors Liver Neoplasms sc [Secondary] ai [Antagonists & Inhibitors] Taxoids Effects] di [Diagnosis] rt [Radiotherapy] 0 (Organoplatinum Compounds) 58-05-9 (Leucovorin) 53643-48-4 (Vindesine) Non-US Gov't Support en [Enzymology] Small Cell Carcinoma 0 (Taxoids) pa [Pathology] 0 (Folfox protocol) Reverse Transcriptase Polymerase Chain Reaction Dihydrouracil Dehydrogenase (NADP) Treatment Outcome ae [Adverse EC 2-1-1-45 (Thymidylate Synthase) Adult Survival Analysis su [Surgery] 33419-42-0 (Etoposide) Feasibility Studies EC 1-3-1-2 (Dihydrouracil Dehydrogenase (NADP)) Rectal Neoplasms Middle Aged Neoplastic Gene Expression Regulation EC 1-17-4 (Ribonucleotide Reductases) Male Organoplatinum Compounds Comparative Study 103882-84-4 (gemcitabine) me [Metabolism] Thymidine Phosphorylase Antineoplastic Antimetabolites Female Human Enzymologic Gene Expression Regulation Colorectal Neoplasms Phytogenic Antineoplastic Agents Predictive Value of Tests North America Antineoplastic Agents Ribonucleotide Reductases 154361-50-9 (capecitabine) EC 2-4-2-4 (Thymidine Phosphorylase) Phytogenic) 0 (Antineoplastic Agents Biological) 0 (Tumor Markers tu [Therapeutic Use] Antineoplastic) 0 (Antimetabolites Cisplatin 80 and over Aged Biological Tumor Markers Disease-Free Survival Lymphatic Metastasis Leucovorin Non-US Gov't Research Support Aged 0 (Antineoplastic Agents) Etoposide Type I DNA Topoisomerases 15663-27-1 (Cisplatin) Survival Rate st [Standards] Vindesine 0 (Enzyme Inhibitors)
Last updated on Wednesday, February 05, 2020